TABLE 2.
Characteristics of metastatic disease in the study population.
| Characteristics | Frequency | Percentage |
| Number of metastatic organs (n = 305) | ||
| <3 | 58 | 19.0 |
| ≥3 | 247 | 81.0 |
| Presence of extraosseous mts (n = 305) | ||
| No | 9 | 3.0 |
| Yes, without brain | 223 | 73.1 |
| Yes, with brain | 73 | 23.9 |
| Time of BM diagnosis (n = 305) | ||
| Synchronous | 50 | 16.4 |
| Metachronous | 255 | 83.6 |
| Sites of BM (n = 300) | ||
| Axial | 165 | 55 |
| Appendicular | 29 | 9.7 |
| Both | 106 | 35.3 |
| Number of BM (n = 301) | ||
| <5 | 183 | 60.8 |
| ≥5 | 118 | 39.2 |
| Calcaemia at BM diagnosis (n = 235) | ||
| ≤ULN | 218 | 92.8 |
| >ULN | 17 | 7.2 |
| LDH levels at BM diagnosis (n = 254) | ||
| ≤2 × ULN | 159 | 62.6 |
| >2 × ULN | 95 | 37.4 |
| Use of BTA (n = 292) | ||
| No | 153 | 52.4 |
| Bisphosphonates | 119 | 40.8 |
| Denosumab | 20 | 6.8 |
| Systemic treatment (n = 291) | ||
| Targeted therapy | 96 | 33.0 |
| Immunotherapy | 114 | 39.2 |
| Targeted and ICIs | 60 | 20.6 |
| Chemotherapy | 21 | 7.2 |
BTA, bone-targeting agents; BM, bone metastases; ICIs, immune checkpoint inhibitors; mts; metastases; LDH, lactate dehydrogenase; ULN, upper limit of normal.